SecBot SecBot
Biotech Drug Report Generated Nov 2, 2026

pegtibatinase

TVTX·Travere Therapeutics, Inc.
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 3
Time to market
If the Phase 3 HARMONY study succeeds, a regulatory filing could follow the topline data (expected 2H 2027), with potential FDA approval potentially 12-18 months later, suggesting a possible 2029-2030 launch at the earliest.
Why 5/10
The next hard catalyst is the pivotal Phase 3 HARMONY topline data readout, guided for the second half of 2027 (roughly 8-14 months from today). Pegtibatinase is a major pipeline asset but Travere also has the approved commercial product FILSPARI generating significant revenue, so the stock is not a pure single-asset binary. No PDUFA date exists.
Actionable Insight NEUTRAL

The next major catalyst is the Phase 3 HARMONY topline data readout in 2H 2027. Positive data would position pegtibatinase as the first disease-modifying therapy for classical HCU and likely drive significant upside. Negative data or further manufacturing delays would be substantially damaging, though FILSPARI revenues provide a partial buffer.

Price Chart

Loading chart...

Executive Summary

Pegtibatinase (TVT-058) is Travere Therapeutics' investigational enzyme replacement therapy for classical homocystinuria (HCU), a rare genetic metabolic disorder with no approved disease-modifying treatment. Phase 1/2 data showed a promising 67% reduction in homocysteine levels, and the drug holds FDA Breakthrough Therapy and Orphan Drug designations. However, the pivotal Phase 3 HARMONY study was paused for over a year due to manufacturing scale-up issues before restarting in early 2026, and topline data is not expected until the second half of 2027. Travere now has a commercially successful approved drug (FILSPARI for kidney diseases) that generated roughly $200M in Q3 2026, reducing dependence on pegtibatinase but also making the pipeline asset less of a pure binary for the stock.

How It Works

Pegtibatinase is an enzyme replacement therapy designed to replace a missing or faulty enzyme (cystathionine beta-synthase, CBS) in patients with classical homocystinuria (HCU), a rare genetic disorder. By supplying a working version of the enzyme, it aims to break down toxic levels of homocysteine that build up in the blood and cause life-threatening blood clots, vision problems, and other complications. The drug is given as a subcutaneous injection.

Trial Status

The pivotal global Phase 3 HARMONY study (NCT06247085) resumed enrollment in Q1 2026 after a voluntary pause from September 2024 due to commercial manufacturing scale-up improvements. The study targets ~70 patients aged 12-65 with total homocysteine levels >= 50 micromol/L despite standard of care. Topline data is expected in the second half of 2027. The prior Phase 1/2 COMPOSE study (NCT03406611) is active but no longer recruiting, having demonstrated a 67.1% mean relative reduction in homocysteine at the highest dose.

The Two-Sided Case

▲ Bull Case5
Phase 1/2 COMPOSE data showed a 67.1% mean relative reduction in total homocysteine at the highest dose, a strong efficacy signal for a therapy with no currently approved disease-modifying alternative.
Pegtibatinase has been granted FDA Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and US/EU Orphan Drug designations, which could accelerate regulatory review and provide market exclusivity.
Multiple sophisticated institutional investors (including Adage Capital, Bank of America, Point72, Marshall Wace, D.E. Shaw, and Wellington Management) added or doubled positions in Q2 2026.
Analyst consensus is Strong Buy (19 analysts: 19 buy-equivalent ratings, 2 hold, 0 sell) with a mean price target of $75.21, implying roughly 52% upside from the current price near $49.
Travere's commercially approved product FILSPARI generated $141M in Q2 2026 and $200M in Q3 2026, providing a strong revenue base that funds the pegtibatinase program without immediate financing risk.
▼ Bear Case5
Manufacturing scale-up problems forced a voluntary enrollment pause of the Phase 3 HARMONY study from September 2024 until Q1 2026, raising execution risk and delaying the program by over a year.
The pivotal Phase 3 topline readout is not expected until the second half of 2027, leaving the stock without a near-term binary catalyst for this program for at least 8-14 months.
Classical HCU is an ultra-rare disease (estimated <3,000 patients in the US), limiting the commercial ceiling even if approved.
CEO Eric Dube and other executives executed significant stock sales (totaling millions of dollars) in September and October 2026 via 10b5-1 plans, which may signal perceived fair valuation.
Short interest stood at 11.58% of estimated shares outstanding as of mid-October 2026, indicating a sizable bearish contingent.

Upcoming Catalysts

  • Phase 3 HARMONY topline efficacy/safety data readout expected 2H 2027
  • Quarterly earnings updates providing enrollment progress on HARMONY study

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Travere Therapeutics, Inc. 8-K TVTX ·Originating report

Sources · 10

Hover a chip for the title
1 businesswire.com2 ir.travere.com3 simianx.ai4 ir.travere.com5 ir.travere.com6 ir.travere.com7 travere.com8 clinicaltrials.gov9 ir.travere.com10 strategicmarketresearch.com